Abstract
<i>Background</i>: Programmed death-ligand 1 (PD-L1) expression at immunohistochemistry is the only approved, but still unsatisfactory, biomarker for immunotherapy in Non-Small Cell Lung Cancer (NSCLC). Neutrophil to Lymphocyte ratio (NLR) is a surrogate of systemic inflammation and could correlate with outcome to immunotherapy. This retrospective study (NCT03816657) explored the role of NLR in predicting benefit to nivolumab and susceptibility to hyperprogression (HPD). <i>Methods</i>: PD-L1, baseline and on-therapy NLR values were available in 173NSCLC patients receiving nivolumab. PD-L1 positivity was defined as expression on ≥1% of tumor cells; NLR was dichotomized in high (≥5) or low (<5). Patients were divided in 4 cohorts: 1 (PD-L1+/low NLR), 2 (PD-L1-/high NLR), 3 (PD-L1+/high NLR), 4 (PD-L1-/low NLR). A landmark analysis explored the impact of cohorts and NLR change on objective response rate (ORR), progression-free survival (PFS), overall survival (OS) and its influence on HPD. <i>Results</i>: PD-L1 was positive in 48% and negative in 52% of cases. Pre-treatment NLR was ≥5in 42% and <5 in 58%of patients; on-treatment NLR was ≥5in approximately 50% of patients. PD-L1 positivity was not associated with outcome. Both high pre- and on-therapy NLR was a negative predictor of ORR (p=0.004), PFS (p<0.0001) and OS (p<0.0001). High NLR cohorts (2 and 4) showed poorer outcome than low NLR cohorts. Relative NLR excursion ≥25% at 4 weeks from nivolumab start was associated with reduced PFS and OS, while its decrease or stability was associated with improved outcomes. Although NLR value and its dynamic did not influence HPD occurrence (p=0.062), 53% of hyperprogressors belonged to high NLR cohorts. <i>Conclusion</i>: The current retrospective analysis supports the role of high NLR as a independent negative predictive factor. Its increment during immunotherapy may identify patients with low likelihood of response to immunotherapy.
Highlights
Over the last 5 years, treatment of advanced non-small cell lung cancer (NSCLC) with unknown driver mutations has been revolutionized by the approval of checkpoint inhibitors as single agents or in combination with chemotherapy in the first-line setting [1,2,3,4,5]
In order to define the difference between nivolumab and chemotherapy-induced HPD, we evaluated the incidence of this unraveling phenomenon in the frontline setting with cisplatin-based chemotherapy versus any line immunotherapy
Our study showed that Neutrophil to Lymphocyte ratio (NLR) value, both at baseline and during treatment, independently correlates with objective response rate (ORR), progression-free survival (PFS) and overall survival (OS) in advanced Non-Small Cell Lung Cancer (NSCLC) treated with nivolumab
Summary
Over the last 5 years, treatment of advanced non-small cell lung cancer (NSCLC) with unknown driver mutations has been revolutionized by the approval of checkpoint inhibitors as single agents or in combination with chemotherapy in the first-line setting [1,2,3,4,5] These advances we are still facing the challenge of the lack of reliable predictive biomarkers of mono-immunotherapy in the second-line scenario. Neutrophil to Lymphocyte ratio (NLR) is a surrogate of systemic inflammation and could correlate with outcome to immunotherapy This retrospective study (NCT03816657) explored the role of NLR in predicting benefit to nivolumab and susceptibility to hyperprogression (HPD). PD-L1 positivity was not associated with outcome Both high pre- and on-therapy NLR was a negative predictor of ORR (p=0.004), PFS (p
Sign-in/Register to view highlights & summary Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callMore From: International Journal of Clinical Oncology and Cancer Research
Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
